Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Jul;84(1):18–27. doi: 10.1172/JCI114138

Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.

J F Eidt 1, P Allison 1, S Noble 1, J Ashton 1, P Golino 1, J McNatt 1, L M Buja 1, J T Willerson 1
PMCID: PMC303947  PMID: 2661588

Abstract

Cyclic variations in coronary blood flow (CFVs) in dogs with experimental coronary artery stenosis and endothelial injury appear to result primarily from the aggregation of platelets at the site of stenosis followed by dislodgement and distal embolization. Using this canine model, we tested the hypotheses: (a) that thrombin is an important mediator of CFVs in dogs with coronary stenoses and endothelial injury; (b) that inhibition of thrombin with heparin, or MCI-9038, a selective thrombin inhibitor, abolishes CFVs in this model; and (c) that abolition of CFVs by thrombin inhibition is time dependent. CFVs, produced in open-chest dogs by placing a flow-reducing plastic constrictor around the left anterior coronary artery, were monitored for either 30 min (group I) or 3 h (group II) before treatment with either heparin or 4-methyl-1-(N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl (MCI-9038). In group I, cyclic flow variations were abolished by heparin in 12 of 18 dogs and by MCI-9038 in 5 of 7 dogs. In group II, cyclic flow variations were not abolished by heparin in any of seven dogs and were abolished by MCI-9038 in only one of seven dogs. Thus, (a) thrombin appears to be an important mediator of cyclic flow variations in dogs with coronary artery stenosis and endothelial injury and (b) inhibition of thrombin abolishes CFVs after short but not prolonged periods of CFVs.

Full text

PDF
18

Images in this article

21Image
on p.21
21Image
on p.21
21Image
on p.21
22Image
on p.22
22Image
on p.22
22Image
on p.22
22Image
on p.22
22Image
on p.22
22Image
on p.22
22Image
on p.22
24Image
on p.24
24Image
on p.24
24Image
on p.24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTER R. H., JANDL J. H. PLATELET SEQUESTRATION IN MAN. I. METHODS. J Clin Invest. 1964 May;43:843–855. doi: 10.1172/JCI104970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ardlie N. G., Packham M. A., Mustard J. F. Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol. 1970 Jul;19(1):7–17. doi: 10.1111/j.1365-2141.1970.tb01596.x. [DOI] [PubMed] [Google Scholar]
  3. Ashton J. H., Benedict C. R., Fitzgerald C., Raheja S., Taylor A., Campbell W. B., Buja L. M., Willerson J. T. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986 Mar;73(3):572–578. doi: 10.1161/01.cir.73.3.572. [DOI] [PubMed] [Google Scholar]
  4. Ashton J. H., Ogletree M. L., Michel I. M., Golino P., McNatt J. M., Taylor A. L., Raheja S., Schmitz J., Buja L. M., Campbell W. B. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987 Oct;76(4):952–959. doi: 10.1161/01.cir.76.4.952. [DOI] [PubMed] [Google Scholar]
  5. Ashton J. H., Schmitz J. M., Campbell W. B., Ogletree M. L., Raheja S., Taylor A. L., Fitzgerald C., Buja L. M., Willerson J. T. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists. Circ Res. 1986 Nov;59(5):568–578. doi: 10.1161/01.res.59.5.568. [DOI] [PubMed] [Google Scholar]
  6. Baruch D., Franssen J., Hemker H. C., Lindhout T. Effect of heparin and low molecular weight heparins on thrombin-induced blood platelet activation in the absence of antithrombin III. Thromb Res. 1985 Jun 1;38(5):447–458. doi: 10.1016/0049-3848(85)90178-1. [DOI] [PubMed] [Google Scholar]
  7. Baruch D., Lindhout T., Wagenvoord R., Hemker H. C. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III. Haemostasis. 1986;16(2):71–81. doi: 10.1159/000215276. [DOI] [PubMed] [Google Scholar]
  8. Bevan J., Heptinstall S. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. Thromb Res. 1983 Jun 1;30(5):415–423. doi: 10.1016/0049-3848(83)90175-5. [DOI] [PubMed] [Google Scholar]
  9. Björk I., Fish W. W. Production in vitro and properties of a modified form of bovine antithrombin, cleaved at the active site by thrombin. J Biol Chem. 1982 Aug 25;257(16):9487–9493. [PubMed] [Google Scholar]
  10. Buchanan M. R., Ofosu F. A., Fernandez F., Van Ryn J. Lack of relationship between enhanced bleeding induced by heparin and other sulfated polysaccharides and enhanced catalysis of thrombin inhibition. Semin Thromb Hemost. 1986 Oct;12(4):324–327. doi: 10.1055/s-2007-1003574. [DOI] [PubMed] [Google Scholar]
  11. Bush L. R., Campbell W. B., Buja L. M., Tilton G. D., Willerson J. T. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984 Jun;69(6):1161–1170. doi: 10.1161/01.cir.69.6.1161. [DOI] [PubMed] [Google Scholar]
  12. Bush L. R., Campbell W. B., Kern K., Tilton G. D., Apprill P., Ashton J., Schmitz J., Buja L. M., Willerson J. T. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res. 1984 Nov;55(5):642–652. doi: 10.1161/01.res.55.5.642. [DOI] [PubMed] [Google Scholar]
  13. Cade J. F., Buchanan M. R., Boneu B., Ockelford P., Cater C. J., Cerskus A. L., Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res. 1984 Sep 15;35(6):613–625. doi: 10.1016/0049-3848(84)90265-2. [DOI] [PubMed] [Google Scholar]
  14. Casu B. Structure of heparins and their fragments. Nouv Rev Fr Hematol. 1984;26(4):211–219. [PubMed] [Google Scholar]
  15. Collen D., De Cock F. A tanned red cell hemagglutination inhibition immunoassay (TRCHII) for the quantitative estimation of thrombin-antithrombin III and plasmin-alpha1-antiplasmin complexes in human plasma. Thromb Res. 1975 Jul;7(1):235–238. doi: 10.1016/0049-3848(75)90140-1. [DOI] [PubMed] [Google Scholar]
  16. Coller B. S., Scudder L. E. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 1985 Dec;66(6):1456–1459. [PubMed] [Google Scholar]
  17. Fenton J. W., 2nd Thrombin. Ann N Y Acad Sci. 1986;485:5–15. doi: 10.1111/j.1749-6632.1986.tb34563.x. [DOI] [PubMed] [Google Scholar]
  18. Fernandez F., N'guyen P., Van Ryn J., Ofosu F. A., Hirsh J., Buchanan M. R. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res. 1986 Aug 15;43(4):491–495. doi: 10.1016/0049-3848(86)90094-0. [DOI] [PubMed] [Google Scholar]
  19. Fitzgerald D. J., Roy L., Catella F., FitzGerald G. A. Platelet activation in unstable coronary disease. N Engl J Med. 1986 Oct 16;315(16):983–989. doi: 10.1056/NEJM198610163151602. [DOI] [PubMed] [Google Scholar]
  20. Folts J. D., Crowell E. B., Jr, Rowe G. G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976 Sep;54(3):365–370. doi: 10.1161/01.cir.54.3.365. [DOI] [PubMed] [Google Scholar]
  21. Folts J. D., Gallagher K., Rowe G. G. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation. 1982 Feb;65(2):248–255. doi: 10.1161/01.cir.65.2.248. [DOI] [PubMed] [Google Scholar]
  22. Fuster V., Chesebro J. H. Mechanisms of unstable angina. N Engl J Med. 1986 Oct 16;315(16):1023–1025. doi: 10.1056/NEJM198610163151608. [DOI] [PubMed] [Google Scholar]
  23. Harmon J. T., Jamieson G. A. Platelet activation by alpha-thrombin is a receptor-mediated event. Ann N Y Acad Sci. 1986;485:387–395. doi: 10.1111/j.1749-6632.1986.tb34599.x. [DOI] [PubMed] [Google Scholar]
  24. Hartley C. J., Hanley H. G., Lewis R. M., Cole J. S. Synchronized pulsed Doppler blood flow and ultrasonic dimension measurement in conscious dogs. Ultrasound Med Biol. 1978;4(2):99–110. doi: 10.1016/0301-5629(78)90035-2. [DOI] [PubMed] [Google Scholar]
  25. Haver V. M., Namm D. H. Characterization of the thrombin-induced contraction of vascular smooth muscle. Blood Vessels. 1984;21(2):53–63. [PubMed] [Google Scholar]
  26. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  27. Hubbell J. A., McIntire L. V. Platelet active concentration profiles near growing thrombi. A mathematical consideration. Biophys J. 1986 Nov;50(5):937–945. doi: 10.1016/S0006-3495(86)83535-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jungi T. W., Spycher M. O., Nydegger U. E., Barandun S. Platelet-leukocyte interaction: selective binding of thrombin-stimulated platelets to human monocytes, polymorphonuclear leukocytes, and related cell lines. Blood. 1986 Mar;67(3):629–636. [PubMed] [Google Scholar]
  29. Kikumoto R., Tamao Y., Tezuka T., Tonomura S., Hara H., Ninomiya K., Hijikata A., Okamoto S. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry. 1984 Jan 3;23(1):85–90. doi: 10.1021/bi00296a014. [DOI] [PubMed] [Google Scholar]
  30. Kumada T., Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor no. 805 (MD-805*) in experimental antithrombin III-deficient animals. Thromb Res. 1981 Nov 15;24(4):285–298. doi: 10.1016/0049-3848(81)90002-5. [DOI] [PubMed] [Google Scholar]
  31. Kumon K., Tanaka K., Nakajima N., Naito Y., Fujita T. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med. 1984 Dec;12(12):1039–1043. doi: 10.1097/00003246-198412000-00008. [DOI] [PubMed] [Google Scholar]
  32. Kurachi K., Fujikawa K., Schmer G., Davie E. W. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry. 1976 Jan 27;15(2):373–377. doi: 10.1021/bi00647a021. [DOI] [PubMed] [Google Scholar]
  33. Marciniak E., Gora-Maslak G. High molecular weight forms of antithrombin III complexes in blood. Thromb Haemost. 1983 Feb 28;49(1):32–36. [PubMed] [Google Scholar]
  34. Matsuo T., Nakao K., Yamada T., Matsuo O. A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. Thromb Res. 1986 Oct 15;44(2):247–251. doi: 10.1016/0049-3848(86)90141-6. [DOI] [PubMed] [Google Scholar]
  35. Matsuo T., Nakao K., Yamada T., Matsuo O. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res. 1986 Jan 1;41(1):33–41. doi: 10.1016/0049-3848(86)90277-x. [DOI] [PubMed] [Google Scholar]
  36. Odegard O. R., Lie M., Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res. 1975 Apr;6(4):287–294. doi: 10.1016/0049-3848(75)90078-x. [DOI] [PubMed] [Google Scholar]
  37. Ofosu F. A., Sie P., Modi G. J., Fernandez F., Buchanan M. R., Blajchman M. A., Boneu B., Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J. 1987 Apr 15;243(2):579–588. doi: 10.1042/bj2430579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ogletree M. L., Harris D. N., Greenberg R., Haslanger M. F., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 Aug;234(2):435–441. [PubMed] [Google Scholar]
  39. Okamoto S., Hijikata A., Kikumoto R., Tonomura S., Hara H., Ninomiya K., Maruyama A., Sugano M., Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun. 1981 Jul 30;101(2):440–446. doi: 10.1016/0006-291x(81)91279-1. [DOI] [PubMed] [Google Scholar]
  40. Rodriguez H. J., Vanderwielen A. J. Molecular weight determination of commercial heparin sodium USP and its sterile solutions. J Pharm Sci. 1979 May;68(5):588–591. doi: 10.1002/jps.2600680519. [DOI] [PubMed] [Google Scholar]
  41. Rosenberg R. D. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975 Jan 16;292(3):146–151. doi: 10.1056/NEJM197501162920307. [DOI] [PubMed] [Google Scholar]
  42. Rosenberg R. D. The effect of heparin on factor XIa and plasmin. Thromb Diath Haemorrh. 1975 Feb 28;33(1):51–62. [PubMed] [Google Scholar]
  43. Saba H. I., Saba S. R., Morelli G. A. Effect of heparin on platelet aggregation. Am J Hematol. 1984 Oct;17(3):295–306. doi: 10.1002/ajh.2830170310. [DOI] [PubMed] [Google Scholar]
  44. Shuman M. A., Majerus P. W. The measurement of thrombin in clotting blood by radioimmunoassay. J Clin Invest. 1976 Nov;58(5):1249–1258. doi: 10.1172/JCI108579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Walz D. A., Anderson G. F., Fenton J. W., 2nd Responses of aortic smooth muscle to thrombin and thrombin analogues. Ann N Y Acad Sci. 1986;485:323–334. doi: 10.1111/j.1749-6632.1986.tb34594.x. [DOI] [PubMed] [Google Scholar]
  46. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  47. Willerson J. T., Campbell W. B., Winniford M. D., Schmitz J., Apprill P., Firth B. G., Ashton J., Smitherman T., Bush L., Buja L. M. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. Am J Cardiol. 1984 Dec 1;54(10):1349–1354. doi: 10.1016/s0002-9149(84)80095-8. [DOI] [PubMed] [Google Scholar]
  48. Willerson J. T., Hillis L. D., Winniford M., Buja L. M. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol. 1986 Jul;8(1):245–250. doi: 10.1016/s0735-1097(86)80121-8. [DOI] [PubMed] [Google Scholar]
  49. de Clerck F., David J. L., Janssen P. A. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions. 1982 Jul;12(3):388–397. doi: 10.1007/BF01965409. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES